Brain-derived neurotrophic factor (BDNF) secreted by neurons is a significant component of synaptic plasticity. In humans, it is also present in blood platelets where it accumulates following its biosynthesis in megakaryocytes. BDNF levels are thus readily detectable in human serum and it has been abundantly speculated that they may somehow serve as an indicator of brain function. However, there is a great deal of uncertainty with regard to the range of BDNF levels that can be considered normal, how stable these values are over time and even whether
Introduction
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family involved in many aspects of neuronal function, as evidenced by a large number of animal experiments as well as human genetics (Zagrebelsky and Korte, 2014) . BDNF is not only found in the brain, but also in circulating platelets in humans (Yamamoto and Gurney, 1990 ) and megakaryocytes have recently been reported to express the same transcripts as neurons (Chacón-Fernández et al., 2016) . As BDNF is released from platelets during the process of blood coagulation, its levels can be readily measured in serum. Even if it is still entirely unclear why BDNF levels in platelets or serum should reflect brain levels (see Discussion), these levels have been associated with a number of conditions including depression (Karege et al., 2002; Sen et al., 2008 ), Huntington's disease (Ciammola et al., 2007; Zuccato et al., 2011) , and Alzheimer's disease (Laske et al., 2006) . However, whether or not BDNF levels can be reliably determined in human serum is increasingly a matter of debate (Zuccato et al., 2011) . In addition, the very large range of reported individual values raises questions as to the plausibility of any disease conditions leading to significant differences in the levels of BDNF in serum. Concerns have also been expressed following reports that different commercially available ELISA kits for measuring BDNF in human serum give different values when the same samples of human serum are tested (Polacchini et al., 2015) . There is then a pressing need to better understand if it is indeed possible to reliably measure BDNF concentrations in human serum before further considering the use of BDNF as a biomarker possibly reflecting disease conditions or for monitoring therapies.
The goal of this study was to address this question with an ELISA based on publically available monoclonal antibodies, using a cohort of 259 healthy volunteers retested after 12 months and to validate the ELISA results using independent Western blot analyses.
Materials and Methods

Serum samples
Serum samples from a cohort of volunteers were collected at the University Hospital of Basel (Switzerland) following a protocol approved by the local ethics committee and in accordance with the terms of the Declaration of Helsinki. All subjects (N ϭ 259, 178 females, 81 males) gave written informed consent. All participants gave a first blood sample (defined as Initial), with most participants (226) agreeing to have a second sample drawn at a 12-month follow-up visit (defined as 12-month). The age range was between 18 and 70 years and the volunteers were of Northern Europe ethnicity. Blood was drawn from a cubital vein into a S-Monovette 7.5 ml Z tube (with clotting activator; Sarstedt), left to coagulate for 30 min at room temperature (RT) and centrifuged at 2000 ϫ g at RT for 10 min. The serum supernatant was stored at -80°C in 0.5 ml aliquots after centrifugation within 1 h of blood sampling. Blood samples for platelet counts and hematocrit values were collected at the same time as blood samples used for the determination of BDNF levels. Time of blood sampling was between 8 A.M. and 12 P.M. in over 75% of the individuals examined.
ELISA
Antibodies
ELISA measurements were performed using a combination of BDNF monoclonal antibodies designated mAb BDNF-#1 and mAb BDNF-#9 (Kolbeck et al., 1999) . Both are available at the Developmental Studies Hybridoma Bank (DSHB), University of Iowa (http://dshb.biology.uiowa.edu). mAb-#1 was conjugated with biotin using sulfo-NHS-LC-Biotin (ThermoFisher Scientific, catalog number 21435). MAb-#9 was conjugated with horseradish peroxidase (HRP) using a peroxidase labeling kit (Roche, 11829696001) following manufacturer's instructions or else provided conjugated by Icosagen.
Protocol
Pierce NeutrAvidin-coated high-capacity plates (ThermoFisher Scientific; 15509) were incubated for two hours at RT with 200 l of 14 g/ml biotin-conjugated mAb-#1 diluted in phosphate buffer (0.1% Triton X-100 in 0.1 M phosphate buffer: 0.1 M KH 2 PO 4 and 0.1 M Na 2 HPO 4 ; pH 7.6). Plates were then washed three times with blocking buffer [1% bovine serum albumin (BSA); Sigma A2153 in phosphate buffer], followed by the addition of 150 l phosphate buffer. A total of 50 l of either standards or diluted samples (both in blocking buffer) was then added to the plate followed by incubation for 3 h at RT on a rotary shaker. The standard was established using recombinant BDNF (Regeneron/Amgen) diluted in blocking buffer. Serum samples were tested at 1:20 dilution, but identical final values were also obtained with 1:10 and 1:40 dilutions. After 3 washes with phosphate buffer, 200 l 1.25 g/ml HRP-conjugated mAb-#9 diluted in blocking buffer was added and incubated for 3 h on a rotary shaker. The plate was then washed three times with phosphate buffer before the addition of 100 l chemiluminescent substrate following manufacturer's instructions (Chemiluminescence ELISA Substrate, Roche 11582950001), and the plate immediately analyzed with a microplate reader (FLUOstar OMEGA, BMG Labtech). Recovery experiments indicated 108.6% recovery of known amounts (30 ng/ml) of recombinant BDNF added to serum samples tested at the typical 1:20 dilution.
Western blotting
One microliter human serum was applied onto a 4 -12% NuPage Bis-Tris gradient gel (Invitrogen), alongside standards consisting of three different quantities of recombinant BDNF (Regeneron/Amgen), typically 15, 30, and 50 pg; 0.1% BSA was added to recombinant BDNF to approximate the composition of the serum samples and to improve the signal consistency between blots. The high level of serum albumin precluded the use of higher volumes of serum and albumin could not be selectively removed from the serum samples without also removing significant (Ͼ50%) amounts of serum BDNF. Proteins were transferred to 0.2 m Protran nitrocellulose membranes (wet or semi-dry transfer at 80 V for 1 h at 4°C or 17V for 1.5 h at RT, respectively) and subsequently blocked for 1 h with a solution containing 3% BSA (Sigma A7906), 3% GE Healthcare ECL Prime Blocking reagent (GE Healthcare) in TBS-T (blocking solution). The membrane was then incubated overnight with primary antibody [1:2000 anti-BDNF (3C11, Icosagen)] in blocking solution. Following three 20-min washes with TBS-T, the membranes were incubated for 1 h with 1:2000 secondary antibody (HRP-conjugated goat anti-mouse IgG1; Invitrogen) in blocking solution, washed once with TBS-T, three times with Lumiglo Reserve wash solution (Insight Biotechnology) and developed using Lumiglo Reserve Chemiluminescent Substrate. Signals were recorded on a ChemiDoc MP Imaging System (Bio-Rad) and quantified using Image Lab V5.0 (Bio-Rad) and BDNF readings only considered when the r 2 value of the standards was above 0.98, and the serum samples readings within the range of the standards. The limit of reliable BDNF detection by Western blotting was 15 ng/ml.
Statistical analysis
As BDNF measurements were not normally distributed the values were log-transformed before analysis of significance. The association between initial BDNF values and both age and gender was assessed using a multivariable linear regression model. Hematocrit and platelet count were included as co-variables. Initial and 12-month BDNF measurements were modeled using generalised estimating equations to examine the association of BDNF to the various predictors while taking into account the dependence of data from the same volunteer. The p value between the first and second measurements was determined using paired t test.
Results
Given various reports on the heterogeneity of values obtained using commercially available BDNF ELISA kits (Polacchini et al., 2015) , a slightly modified version of a previously described ELISA protocol was used (Kolbeck et al., 1999 ) based on publically available BDNF monoclonal antibodies (http://dshb.biology.uiowa.edu/). This assay has an interassay coefficient of variability of 8.8% as calculated with a single serum sample measured on 18 different plates [24.11 Ϯ 2.12 ng/ml (SD); range, 20.63-28.66 ng/ml]. The intra-assay coefficient of variability was calculated as 9.7% based on 253 samples tested in triplicate. This ELISA was used to determine the serum BDNF levels in a cohort of volunteers (n ϭ 259) and to monitor these levels in most of these volunteers (n ϭ 226) over a 12-month period. Cohort demographics are listed in Table 1 . Serum samples were collected following a strict protocol (see Methods), as the procedures used to collect the blood samples and to generate serum following blood collection are expected and indeed known to cause variability given that the bulk of BDNF eventually measured in serum is released from platelets (see Discussion). The values determined in the serum of 259 healthy volunteers are summarized in Table 2 . The mean serum value (ϮSD) of BDNF at the first visit was 32.69 Ϯ 8.33 ng/ml; the median value was 30.86 ng/ml. The mean serum value in participants 12 months later was 32.97 Ϯ 8.36 ng/ml with a median of 32.27 ng/ml (Fig. 1), i.e., statistically indistin- Fig. 1 ) with 37 individuals showing Ͼ20% changes. In Figure 1 , they are connected by either yellow (20 -30% change) or red lines (Ͼ30% change). The range of BDNF serum values was 15.83-79.77 ng/ml, with a small, positive correlation with age indicating an increase in serum BDNF levels of 0.33% for every year of age ( Fig. 2 ; p ϭ 0.031). The values of BDNF content per platelet also indicate a significant, positive correlation with age when pooling the corresponding data (N ϭ 475, p ϭ 0.03; Fig. 3A ). Platelet counts also significantly (p Ͻ 0.001; Fig. 3B ) correlated with BDNF values with an increase of 14.5% seen with every 100 ϫ 10 9 increase in platelets. As reported previously (Butkiewicz et al., 2006) , there was a significant difference in platelet counts between genders (p ϭ 0.0273) with mean platelet counts (geometric mean) of 274.62 ϫ 10 9 per ml blood for female and 255.62 ϫ 10 9 for male volunteers. In addition, there is a significant association between BDNF levels and hematocrit (p ϭ 0.001; Fig. 4 ). Mean hematocrit values (geometric mean) were 39.52% for female and 44.04% for male volunteers, reflecting the known gender difference (p Ͻ 0.001; Vahlquist, 1950) . However, no significant gender-dependent differences were observed with regard to the BDNF values in serum.
These ELISA results can also be used to estimate the size of the cohorts needed to generate statistically significant results. Assuming equal group sizes, a variability of the measurements of 0.24 (as observed here) and a t test of log-normally distributed data with a significance level of 0.05, group sizes of 60 and 200 will be needed to measure group differences of 20% or 10%, respectively, with 80% power (Fig. 5) .
To validate these ELISA results, a subset of the collected serum samples representing the lower and upper ranges was analyzed by Western blotting (10 samples in total; Fig. 6 ).
Discussion
Using the publicly available monoclonal antibodies mAb BDNF-#1 and mAb BDNF-#9 and avidin-coated ELISA plates, mean levels of BDNF in serum were found to be stable over a period of 12 months among the 226 retested volunteers. Within the cohort, single values ranged from a low 15.83 ng/ml to a high 79.77 ng/ml despite a rigorous serum collection protocol. The need to examine large cohorts is further illustrated by the finding that as many as 37 individuals, i.e., ϳ16% of the retested volunteers, had values that differed by 20% or more 12 months after the initial samples were collected. Importantly, the mean values reported here could be confirmed by Western blot analysis using a recently developed BDNF monoclonal antibody allowing the detection of BDNF in serum samples without pretreatment. Attempts to deplete samples of major serum proteins, including antibody-mediated adsorption or protein precipitation failed as they led to losses of BDNF of at least 50% when serum levels were determined by ELISA before and after protein depletion. While the mean BDNF serum values reported here fall within the range of a small number of other studies Lommatzsch et al., 2005; Ziegenhorn et al., 2007) , the published average values range from below 1 ng/ml (Onen Sertoz et al., 2008) to over 60 ng/ml (Matrisciano et al., 2009 ). This New Researchvariability has been previously explained by issues related to serum collection (Maffioletti et al., 2014; Tsuchimine et al., 2014) and to commercially available antibodies, including antibody precoated plates (Polacchini et al., 2015) . In megakaryocytes BDNF is co-stored in ␣ granules with PF4 (Chacón-Fernández et al., 2016) and neither in megakaryocytes nor in pro-platelets did we find any evidence for a cytoplasmic storage of BDNF (Tamura et al., 2011), and it seems that only a fraction of the BDNF content is released during the process of degranulation (SerraMillas, 2016 ). This partial release may be a consequence of the dense BDNF packaging in platelets, its association with other components in ␣ granules and/or a consequence of its physico-chemical properties, including its high isoelectric point and hydrophobicity (Barde et al., 1982; Hofer and Barde, 1988) . In addition, various commonly used drugs including those known to interfere with the biosynthesis of prostaglandins or of adenosine diphosphate are likely to interfere with the release of BDNF from platelets given their established roles in platelet aggregation (Stoll et al., 2011) . A major reason for the large number of publications reporting on BDNF levels in serum is the intriguing association with numerous conditions including depression (Karege et al., 2002; Sen et al., 2008) and neurodegenerative disorders such as Alzheimer's disease (Laske et al., 2006; Lee et al., 2009; Forlenza et al., 2010) , Parkinson's disease (Scalzo et al., 2010; Costa et al., 2015; Wang et al., 2016) , and Huntington's disease (Ciammola et al., 2007; Zuccato et al., 2011) . Conversely, BDNF levels have also been reported to increase after acute exercise (Rojas Vega et al., 2006; Dinoff et al., 2017) . While the reality of an association between the levels of BDNF in serum and any conditions has been questioned (Zuccato et al., 2011) , the results of several meta-analyses suggest that these associations may be real (Brunoni et al., 2008; Molendijk et al., 2014; Szuhany et al., 2015) . Importantly, post-mortem analyses of BDNF brain content do indicate correlations between brain levels of BDNF and the rate of cognitive decline in diseases such as Alzheimer's or Parkinson's (Howells et al., 2000; Buchman et al., 2016) and in depression (Thompson Ray et al., 2011) . However, there is still no plausible mechanism satisfactorily explaining how BDNF levels in blood may reflect levels in the brain. The hypothesis that platelets may somehow accumulate BDNF following its diffusion from the brain into the vascular compartment appears unlikely. Beside the lack of BDNF transporter in platelets (Fujimura et al., 2002) , intravenous injections of radiolabeled BDNF into rats failed to show any accumulation in the brain, indicating the inability of BDNF to cross the blood-brain barrier (Pardridge et al., 1994) . Furthermore, while rats and mice express similar levels of BDNF in the brain, BDNF can be readily detected in platelets and serum of rats, but not of mice. The more plausible source accounting for the presence of BDNF in platelets are the plateletgenerating cells, namely megakaryocytes: they contain readily detectable levels of BDNF in rats and humans, but (Chacón-Fernández et al., 2016) . Given the additional finding that neuron-specific BDNF transcripts have been detected in megakaryocytes it is conceivable that conditions affecting BDNF transcription both in neurons and megakaryocytes may explain correlations between the levels of BDNF in serum and in brain. However, such transcriptional changes are unlikely to explain BDNF increases after acute physical exercise whereby increased release of BDNF from platelets, for example, as a result of their fragmentation or activation, may appear more likely (Posthuma et al., 2015) . In general, as is the case for several other growth factors and cytokines contained in platelets, the functional relevance of BDNF in platelets is still unclear though it is intriguing to note that the serum levels of BDNF in all primates tested are comparable to those found in humans (Mori et al., 2003) . Accumulation of BDNF in platelets may have conferred a survival advantage in long-lived species, for example by contributing to tissue repair like may be the case for other platelet-derived growth factors and cytokines. Among the various parameters tested, platelet numbers were found to be the variable most significantly correlated with BDNF serum values, in line with the fact that platelets are the major source of BDNF in serum. However, this correlation was not as strong as may have been anticipated (Fig. 3) . Furthermore, while a significant difference in platelet counts was found between genders (p ϭ 0.0273) as previously reported (Butkiewicz et al., 2006 ) no significant differences in the levels of BDNF between genders could be observed, presumably a consequence of the relatively weak correlation between BDNF values and platelet counts. Also, while platelet numbers are known to decrease with age a moderate increase in BDNF serum levels was observed with age (p ϭ 0.03; Fig. 3) . It thus appears that factors others than platelet numbers also contribute to BDNF levels in serum, including platelet reactivity. For example, it has been previously noted that the release of ␣ granule components such as PF4 increases with age, for reasons that remain unclear (Zahavi et al., 1980) .
In conclusion, the results demonstrate that BDNF levels can be reliably measured in human serum samples using publicly available monoclonal antibodies. However, meaningful comparisons require the recruitment of adequately-sized cohorts given individual variations.
